Mario Salvi - Concepedia

Author

Mario Salvi

Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico ORCID

Also Known As

M G Salvi, M SALVI, M Salvi, M. Marinò, M. SALVI, M. Salvi, MARIO SALVI, Mario Giovanni Salvi, Mario Salvi, P Saeed

260

Publications

10.5K

Citations

H-Index

Concepts

All Affiliations

Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico University of Milan University of Parma University of Pisa Montreal General Hospital

About

Mario Salvi is an author at Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico specializing in medicine, ophthalmology, and thyroid disorders.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	27	41	4.2K
2	Public Health	6	6	469
3	Health Sciences	2	2	25
4	Engineering	1	1	49
5	Social Sciences	1	1	40

Mario Salvi

Publications

9.2K

Citations

H-Index

Page 1

	Year	Citations
The 2016 European Thyroid Association/European Group on Graves' Orbitopathy Guidelines for the Management of Graves' Orbitopathy Luigi Bartalena, Lelio Baldeschi, Kostas Boboridis, European Thyroid Journal Translational MedicineSelenium DeficiencyThyroid DiseasePharmacologyParathyroid Disease	2016	937
Consensus statement of the European Group on Graves' orbitopathy (EUGOGO) on management of GO Luigi Bartalena, Lelio Baldeschi, Alison Dickinson, European Journal of Endocrinology Critical Care MedicineTourgent Surgical Decompression.cOphthalmologyOculoplasticsMild Go	2008	786
Teprotumumab for Thyroid-Associated Ophthalmopathy Terry J. Smith, George J. Kahaly, Daniel G. Ezra, New England Journal of Medicine	2017	693
Teprotumumab for the Treatment of Active Thyroid Eye Disease Raymond S. Douglas, George J. Kahaly, Amy Patel, New England Journal of Medicine	2020	656
Consensus Statement of the European Group on Graves' Orbitopathy (EUGOGO) on Management of Graves' Orbitopathy Luigi Bartalena, Lelio Baldeschi, Alison Dickinson, Thyroid Thyroid DiseaseSurgeryConsensus StatementMedicineEuropean Group	2008	406
Efficacy of B-Cell Targeted Therapy With Rituximab in Patients With Active Moderate to Severe Graves' Orbitopathy: A Randomized Controlled Study Mario Salvi, Guia Vannucchi, Nicola Currò, The Journal of Clinical Endocrinology & Metabolism	2014	390
Efficacy and Safety of Three Different Cumulative Doses of Intravenous Methylprednisolone for Moderate to Severe and Active Graves' Orbitopathy Luigi Bartalena, G. E. Krassas, Wilmar M. Wiersinga, The Journal of Clinical Endocrinology & Metabolism	2012	353
SARS-CoV-2-related atypical thyroiditis Ilaria Muller, Daniele Cannavaro, Davide Dazzi, The Lancet Diabetes & Endocrinology Thyroid DiseaseSars-cov-2-related Atypical ThyroiditisCovid-19	2020	311
Treatment of Graves’ disease and associated ophthalmopathy with the anti-CD20 monoclonal antibody rituximab: an open study Mario Salvi, Guia Vannucchi, Irene Campi, European Journal of Endocrinology	2007	262
Mycophenolate plus methylprednisolone versus methylprednisolone alone in active, moderate-to-severe Graves' orbitopathy (MINGO): a randomised, observer-masked, multicentre trial George J. Kahaly, Michaela Riedl, J. König, The Lancet Diabetes & Endocrinology Methylprednisolone Versus MethylprednisoloneEndocrine DiseaseMedicineClinical TrialsMulticentre Trial	2018	212

Page 1